-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Roflumilast N-oxide-[d4]
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/1794760-31-8.gif)
| Category | Respiratory syncytial Virus (RSV) |
| CAS | 1794760-31-8 |
| Description | A deuterated impurity of Roflumilast. Roflumilast is a selective, long-acting inhibitor of the enzyme phosphodiesterase-4 (PDE-4). |
Product Information
| Synonyms | Roflumilast-d4 N-Oxide; 3-(Cyclopropylmethoxy-d4)-N-(3,5-dichloro-1-oxido-4-pyridinyl)-4-(difluoromethoxy)benzamide; N-(3,5-Dichloro-1-oxopyridin-4-yl)-4-difluoromethoxy-3-(cyclopropyl-d4) methoxybenzamide |
| IUPAC Name | N-(3,5-dichloro-1-hydroxypyridin-4-ylidene)-4-(difluoromethoxy)-3-[(2,2,3,3-tetradeuteriocyclopropyl)methoxy]benzamide |
| Molecular Weight | 423.24 |
| Molecular Formula | C17H10Cl2F2N2O4D4 |
| Canonical SMILES | C1CC1COC2=C(C=CC(=C2)C(=O)N=C3C(=CN(C=C3Cl)O)Cl)OC(F)F |
| InChI | InChI=1S/C17H14Cl2F2N2O4/c18-11-6-23(25)7-12(19)15(11)22-16(24)10-3-4-13(27-17(20)21)14(5-10)26-8-9-1-2-9/h3-7,9,17,25H,1-2,8H2/i1D2,2D2 |
| InChIKey | KHXXMSARUQULRI-LNLMKGTHSA-N |
| Boiling Point | 519.7±50.0 °C at 760 mmHg |
| Melting Point | >176°C (dec.) |
| Flash Point | 268.1±30.1 °C |
| Purity | > 95% |
| Density | 1.6±0.1 g/cm3 |
| Solubility | DMF: 30 mg/ml, DMSO: 20 mg/ml, Ethanol: 10 mg/ml |
| Appearance | Light Beige Solid |
| Storage | Store at -20°C |
| Complexity | 645 |
| Exact Mass | 422.0549756 |
| Index Of Refraction | 1.616 |
| In Vitro | Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and Metabolic profiles of drugs. |
| Target | Phosphodiesterase (PDE); RSV |
| Vapor Pressure | 0.0±1.4 mmHg at 25°C |
| XLogP3-AA | 4.8 |
